Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.46 USD
-0.03 (-5.33%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.45 -0.01 (-1.51%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SGMO 0.46 -0.03(-5.33%)
Will SGMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for SGMO
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ...
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Sangamo Therapeutics GAAP EPS of -$0.08 misses by $0.04, revenue of $18.3M misses by $13.38M